MetLife Investment Management’s Cidara Therapeutics CDTX Stock Holding History

MetLife Investment Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,799	Closed	-$2.39M	–	2778
2025 Q4	$2.39M	Buy	10,799 +1,465	+16%	+$237K	0.01%	990
2025 Q3	$894K	Sell	9,334 -751	-7%	-$47.9K	﹤0.01%	1509
2025 Q2	$491K	Buy	+10,085	New	+$242K	﹤0.01%	1684

MetLife Investment Management's CDTX Position: Q1 2026 in Review

MetLife Investment Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 10,799 shares — an estimated $2.39M sold.

MetLife Investment Management first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $2.39M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

MetLife Investment Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
MetLife Investment Management sold 10,799 Cidara Therapeutics shares in Q1 2026, an estimated $2.39M.
MetLife Investment Management first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
MetLife Investment Management's Cidara Therapeutics position peaked at $2.39M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.